

## Corporate News

April 12, 2017

### MagForce AG participates in six upcoming international conferences in Q2 2017

**Berlin, Germany and Nevada, USA, April 12, 2017** - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in six upcoming scientific and investor conferences in the second quarter 2017:

- **5<sup>th</sup> Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS)**  
Date: May 04-07, 2017  
Location: Zurich, Switzerland  
Lunch Symposium: "Focal Therapy in Glioblastoma - Current Status | What's New?!"  
Saturday, May 06, 2017, 12:15-13:15 CEST
- **8<sup>th</sup> DVFA Spring Conference 2017**  
Date: May 08-10, 2017  
Location: Frankfurt am Main, Germany  
Presentation: Ben J. Lipps, CEO of MagForce AG, Wednesday, May 10, 2017
- **Goldman Sachs European Small & Mid-Cap Symposium**  
Date: May 11, 2017  
Location: London, United Kingdom  
Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, May 11, 2017
- **Berenberg European Conference USA 2017**  
Date: May 22-24, 2017  
Location: Tarrytown, New York, USA  
Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, May 23, 2017
- **Deutsche Bank 20th Annual dbAccess German, Swiss & Austrian Conference**  
Date: June 21-23, 2017  
Location: Berlin, Germany  
Presentation: Ben J. Lipps, CEO of MagForce AG, Wednesday, June 21, 2017
- **Long Night of the Sciences (Lange Nacht der Wissenschaften)**  
Date: June 24, 2017  
Location: Berlin and Potsdam, Germany

#### Corporate News

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • [www.magforce.com](http://www.magforce.com)

For further information:  
Barbara von Frankenberg  
VP Communications  
& Investor Relations

[bfrankenberg@magforce.com](mailto:bfrankenberg@magforce.com)  
**T** +49-30-308380-77  
**F** +49-30-308380-99  
**M** +49 173-2792768

**About MagForce AG and MagForce USA, Inc.**

MagForce AG, listed in the new Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm® therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: [www.magforce.com](http://www.magforce.com)

Get to know our Technology: [video \(You Tube\)](#)

Stay informed and subscribe to our [mailing list](#)

**Disclaimer**

*This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.*

**Corporate News**

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • [www.magforce.com](http://www.magforce.com)

For further information:  
Barbara von Frankenberg  
VP Communications  
& Investor Relations

[bfrankenberg@magforce.com](mailto:bfrankenberg@magforce.com)  
**T** +49-30-308380-77  
**F** +49-30-308380-99  
**M** +49 173-2792768